Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4794201
Max Phase: Preclinical
Molecular Formula: C40H53N9O9S
Molecular Weight: 835.98
Molecule Type: Unknown
Associated Items:
ID: ALA4794201
Max Phase: Preclinical
Molecular Formula: C40H53N9O9S
Molecular Weight: 835.98
Molecule Type: Unknown
Associated Items:
Canonical SMILES: N=C(N)Nc1cc(NC(=O)CCCCNC(=O)C23CC4CC(CC(C4)C2)C3)cc(C(=O)NCC(=O)NC[C@H](NC(=O)[C@@H]2CCCN2S(=O)(=O)c2ccccc2)C(=O)O)c1
Standard InChI: InChI=1S/C40H53N9O9S/c41-39(42)47-29-17-27(16-28(18-29)46-33(50)10-4-5-11-43-38(56)40-19-24-13-25(20-40)15-26(14-24)21-40)35(52)45-23-34(51)44-22-31(37(54)55)48-36(53)32-9-6-12-49(32)59(57,58)30-7-2-1-3-8-30/h1-3,7-8,16-18,24-26,31-32H,4-6,9-15,19-23H2,(H,43,56)(H,44,51)(H,45,52)(H,46,50)(H,48,53)(H,54,55)(H4,41,42,47)/t24?,25?,26?,31-,32-,40?/m0/s1
Standard InChI Key: PCEMPIMHMWVATP-OONSMZQZSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 835.98 | Molecular Weight (Monoisotopic): 835.3687 | AlogP: 1.70 | #Rotatable Bonds: 18 |
Polar Surface Area: 282.08 | Molecular Species: ZWITTERION | HBA: 9 | HBD: 9 |
#RO5 Violations: 2 | HBA (Lipinski): 18 | HBD (Lipinski): 10 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 3.03 | CX Basic pKa: 9.03 | CX LogP: -0.97 | CX LogD: -0.98 |
Aromatic Rings: 2 | Heavy Atoms: 59 | QED Weighted: 0.06 | Np Likeness Score: -1.13 |
1. Sundaram A,Chen C,Isik Reed N,Liu S,Ki Yeon S,McIntosh J,Tang YZ,Yang H,Adler M,Beresis R,Seiple IB,Sheppard D,DeGrado WF,Jo H. (2020) Dual antagonists of α5β1/αvβ1 integrin for airway hyperresponsiveness., 30 (22): [PMID:33007395] [10.1016/j.bmcl.2020.127578] |
Source(1):